中国肝脏病杂志(电子版)

位置：首页 >> 期刊文章

恩替卡韦联合干扰素及利巴韦林治疗HBV、HCV重叠感染87例临床观察

作者：高鹏

单位：河南省传染病医院郑州 450015

关键词：HBV HCV 重叠感染恩替卡韦干扰素

分类号：

出版年,卷(期):页码：2015,7(4):113-115

摘要：

摘要：目的对恩替卡韦联合干扰素（IFN）α-2b及利巴韦林片治疗HBV与HCV重叠感染的疗效进行
观察。方法选择2010年6月至2014年6月河南省传染病医院乙型肝炎病毒（HBV）及丙型肝炎病毒
（HCV）重叠感染的慢性肝炎患者87例，随机分为两组，试验组49例，对照组38例，两组均用IFN-
α-2b（安福隆）5 × 10 6 U，肌内注射，隔日1次，利巴韦林片0.9 g/d，疗程48周，均口服护肝药（甘
草酸二铵肠溶胶囊）治疗1个月。试验组：加用恩替卡韦片（博路定）0.5 mg/d，口服。对照组：不
加恩替卡韦片。观察两组患者HCV RNA、HBV DNA、ALT复常率的变化。结果治疗48周时，试验
组的治疗有效率为53.0%，高于对照组的31.57%（χ 2 = 3.4536，P = 0.036）。结论对于HBV与HCV
重叠感染的患者，恩替卡韦联合干扰素及利巴韦林治疗效果显著优于单用干扰素治疗。

Abstract: Objective To observe the curative effect of entecavir combined with interferon and ribavirin
in treatment of HBV and HCV coinfection. Methods From June 2010 to June 2014, 87 patients with
HBV and HCV coinfection in Henan Infectious Disease Hospital were divided into experimental group
and control group randomly, 49 cases in the experimental group and 38 cases in the control group. Both
groups were given interferon 5 × 10 6 U by intramuscular injection and ribavirin tablets 0.9 g/d orally,
the course of treatment was 48 weeks. The two groups were also given diammonium glycyrrhetate
(DG) enteric capsules orally for 1 month. On this basis, the experimental group were given entecavir
(Baraclude) 0.5 mg/d orally. The normalization rates of HCV RNA, HBV DNA and ALT of the two
groups were observed. Results After 48 weeks’ treatment, the effective rate of the experimental group
(53%) was higher than that of the control group (31.57%) (χ 2 = 3.4536, P = 0.036). Conclusion The
efficacy of entecavir combined with interferon and ribavirin in treatment with HBV and HCV coinfection
was better than interferon alone.

基金项目：

作者简介：

参考文献：

服务与反馈：

【文章下载】【加入收藏】